Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.

Johannes Waldschmidt, Dagmar Wider, Marie Follo, PhD, Josefina Udi, MD, Martina Kleber, Joschka Lorenz, Gabriele Ihorst, Ralph Wäsch, Monika Engelhardt

Blood (2012) 120 (21): 2450.

https://doi.org/10.1182/blood.V120.21.2450.2450

Published: 2012

Journal Articles

Dissecting Stem Cell Proliferation and Differentiation in Association with the Central Cell Cycle Regulator APC/C Cdh1

Daniel Ewerth, Andrea Schmidts, Birgit Kuegelgen, Dagmar Wider, Julia Schüler, Monika Engelhardt, Ralph Wäsch, MD

Blood (2012) 120 (21): 1236.

https://doi.org/10.1182/blood.V120.21.1236.1236

Published: 2012

Journal Articles

A Rationale to Enhance the Response to Antimitotic Therapy in Acute Myeloid Leukemia

Dominik Schnerch, MD, Julia Felthaus, Monika Engelhardt, Ralph Wäsch, MD

Blood (2012) 120 (21): 1332.

https://doi.org/10.1182/blood.V120.21.1332.1332

Published: 2012

Journal Articles

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Bernd Koch, Gabriele Ihorst, Ralph Wäsch, Martin Schumacher, Monika Engelhardt

Blood (2012) 120 (21): 4982.

https://doi.org/10.1182/blood.V120.21.4982.4982

Published: 2012

Journal Articles

The Spindle Checkpoint Protein BubR1 Is Differentially Expressed in the Lymphatic and Myeloid Lineage and Is a Determinator of Response to Spindle Poisons

Dominik Schnerch, MD, Marie Follo, PhD, Andrea Schmidts, Julika Krohs, Julia Felthaus, Monika Engelhardt, MD, Ralph Wäsch

Blood (2011) 118 (21): 1407.

https://doi.org/10.1182/blood.V118.21.1407.1407

Published: 2011

Journal Articles

Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation

Jesus Duque-Afonso, Antje Prasse, Ralph Wäsch, Hartmut Bertz, Jurgen Finke, MD, Reinhard E Marks

Blood (2010) 116 (21): 1266.

https://doi.org/10.1182/blood.V116.21.1266.1266

Published: 2010

Journal Articles

In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.

Josefina Udi, Dagmar Wider, Gabriele Ihorst, Julia Schüler, Ralph Wäsch, Monika Engelhardt

Blood (2009) 114 (22): 4922.

https://doi.org/10.1182/blood.V114.22.4922.4922

Published: 2009

Journal Articles

Higher Vascular Endothelial Growth Factor (VEGF) and Endothelial Progenitor Cells (EPCs) in Multiple Myeloma (MM) Patients (pts) as a Reflection of Their Governing Role in Pathological Angiogenesis: Comparison of VEGF and EPC Levels Between Healthy Donors (HD), MGUS and MM Pts and Correlation Analysis with MM Activity

Josefina Udi, Martina Kleber, Dagmar Wider, Ralph Wäsch, Monika Engelhardt

Blood (2008) 112 (11): 5132.

https://doi.org/10.1182/blood.V112.11.5132.5132

Published: 2008

NARROW

Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.

Dissecting Stem Cell Proliferation and Differentiation in Association with the Central Cell Cycle Regulator APC/C Cdh1

A Rationale to Enhance the Response to Antimitotic Therapy in Acute Myeloid Leukemia

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

The Spindle Checkpoint Protein BubR1 Is Differentially Expressed in the Lymphatic and Myeloid Lineage and Is a Determinator of Response to Spindle Poisons

Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation

In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only